Rao Chunbao, Yang Fan, Lai Zhijun, Chen Sujun, Lu Xiaomei, Jiang Xiaoyun
Department of Pediatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
Scientific Research Center, Children's Hospital of Dongguan, Dongguan, Guangdong 523000, P.R. China.
Exp Ther Med. 2020 Nov;20(5):67. doi: 10.3892/etm.2020.9195. Epub 2020 Sep 9.
Peptide profiles change significantly with aging and peptide biomarkers discovered in adult patients may not be suitable for the evaluation of pediatric patients. The present study was designed to explore alterations in the serum peptidome profile of pediatric patients with IgA nephropathy (IgAN). A total of 17 children diagnosed with IgAN were recruited as the experimental group, 11 sex-matched healthy children were recruited as a healthy control group and 18 sex-matched children with other glomerular diseases were recruited as a disease control group. Serum peptides of each subject were enriched and analyzed by liquid chromatography with tandem mass spectrometry and the subsequently identified IgAN-specific peptides were evaluated using Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Subsequently, the function of the IgAN-specific peptides was predicted via sequence comparison with other known functional bioactive peptides. A total of 123 peptides with a fold change >2 (P<0.05) and 48 peptides with a fold change >5 (P<0.05) were identified to be differentially expressed between the pediatric IgAN group and the two other groups. Consequently, two putative peptides that may have bioactive effects in the pathogenesis of IgAN in pediatric patients were identified. The serum peptidome profile of pediatric patients with IgAN was significantly different from the disease control group and the healthy control group. These differentially expressed peptides may serve as biomarkers for the minimally invasive diagnosis of pediatric patients with IgAN. Additionally, the potential bioactive peptides specifically expressed in pediatric IgAN patients that were identified in this study may lay a foundation for exploring new therapies for IgAN, such as the creation of novel peptide drugs.
肽谱会随着年龄的增长而发生显著变化，在成年患者中发现的肽生物标志物可能不适用于儿科患者的评估。本研究旨在探讨IgA肾病（IgAN）儿科患者血清肽组谱的变化。共招募了17名被诊断为IgAN的儿童作为实验组，11名性别匹配的健康儿童作为健康对照组，18名性别匹配的患有其他肾小球疾病的儿童作为疾病对照组。通过液相色谱串联质谱对每个受试者的血清肽进行富集和分析，并使用基因本体富集和京都基因与基因组百科全书通路分析对随后鉴定出的IgAN特异性肽进行评估。随后，通过与其他已知功能的生物活性肽进行序列比较，预测IgAN特异性肽的功能。在儿科IgAN组与其他两组之间，共鉴定出123个变化倍数>2（P<0.05）的肽和48个变化倍数>5（P<0.05）的肽存在差异表达。因此，鉴定出了两种可能在儿科患者IgAN发病机制中具有生物活性作用的推定肽。IgAN儿科患者的血清肽组谱与疾病对照组和健康对照组有显著差异。这些差异表达的肽可能作为儿科IgAN患者微创诊断的生物标志物。此外，本研究中鉴定出的在儿科IgAN患者中特异性表达的潜在生物活性肽可能为探索IgAN的新疗法奠定基础，例如开发新型肽药物。
